

Ethanol Gen.2**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
03183777 190	Ethanol Gen.2 100 tests	System-ID 07 6611 9 Roche/Hitachi cobas c 311, cobas c 501/502
20751995 190	Ammonia/Ethanol/CO2 Calibrator (2 x 4 mL)	Code 688
20752401 190	Ammonia/Ethanol/CO2 Control Normal (5 x 4 mL)	Code 100
20753009 190	Ammonia/Ethanol/CO2 Control Abnormal (5 x 4 mL)	Code 101

English**System information**

For **cobas c** 311/501 analyzers:

ETOH2: ACN 703

SETH2: ACN 671 (STAT, reaction time: 5)

For **cobas c** 502 analyzer:

ETOH2: ACN 8703

SETH2: ACN 8671 (STAT, reaction time: 5)

Intended use

In vitro test for the quantitative determination of ethanol in human serum, plasma and urine on Roche/Hitachi **cobas c** systems.

Summary


Ethyl alcohol determinations are among the most frequent analyses required in the forensic and clinical toxicology laboratory. Ethyl alcohol measurements are used in the diagnosis and treatment of alcohol intoxication and poisoning.

Early techniques for blood alcohol determination used distillation, aeration, or diffusion to separate the alcohol from the plasma matrix. The distilled alcohol was then measured by oxidation of the alcohol by strong oxidizing agents. However, these methods lacked specificity, since other oxidizable compounds could also be distilled into and react in the reaction mixture.¹ While there are many acceptable published procedures, including gas chromatographic and osmometric methods, the enzymatic technique described below, based on the information given by Bucher and Redetzki², is specific and simple to perform.

Test principle

Enzymatic method with alcohol dehydrogenase.

Ethyl alcohol and NAD are converted to acetaldehyde and NADH by ADH.



The NADH formed during the reaction, measured photometrically as a rate of change in absorbance, is directly proportional to the ethyl alcohol concentration.

Reagents - working solutions

R1 Buffer; preservatives

R2 NAD (yeast): ≥ 3 mmol/L; ADH (EC 1.1.1.1; yeast; 25 °C): ≥ 617 $\mu\text{kat/L}$ (37 U/mL); stabilizers; preservatives

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: For prescription use only.

Reagent handling

Ready for use

Storage and stability**ETOH2**

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

Specimen collection and preparation^{3,4}

Do not use alcohol or other volatile disinfectants at the site of venipuncture. Aqueous Zephiran (benzalkonium chloride), aqueous Merthiolate (thimerosal), or povidone-iodine may be used.

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum, Plasma: Li-heparin and K₂-EDTA

Stability:⁵ 2 days at 25 °C

2 weeks at 5 °C

4 weeks at -15 °C

Plasma: NaF/Na₂-EDTA and NaF/K-Oxalate

Stability:⁵ 2 weeks at 25 °C

3 months at 5 °C

6 months at -15 °C

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Urine: Use random urine.

Stability:⁶ 30 days at 4 °C

Storage: Samples must be tightly closed.

Centrifuge samples containing precipitates before performing the assay.

Each laboratory should establish guidelines for determining acceptability of specimens and the corrective action to be taken if a specimen is considered unacceptable.

With respect to specimens procured for medicolegal purposes, each legal jurisdiction may have specific requirements concerning the collection and storage of specimens from living subjects, which should be followed as rigorously as possible.⁷

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

See "Order information" section

General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Repeat assays must be performed on freshly poured cups, due to evaporation of alcohol.

When using Ammonia/Ethanol/CO2 Calibrator: Do not leave calibrator cups open for longer than 30 minutes at 15-25 °C.

When using Ammonia/Ethanol/CO2 Controls: Do not leave control cups open for longer than 1 hour at 15-25 °C.

Application for serum, plasma and urine**cobas c 311 test definition**

Assay type	2-Point End	
Reaction time / Assay points	10 / 14-23 (STAT 5 / 14-23)	
Wavelength (sub/main)	700/340 nm	
Reaction direction	Increase	
Units	mmol/L (g/L, mg/dL)	
Reagent pipetting	Diluent (H ₂ O)	
R1	50 µL	–
R2	50 µL	–

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H ₂ O)
Normal	4 µL	–	–
Decreased	2 µL	–	–
Increased	4 µL	–	–

cobas c 501 test definition

Assay type	2-Point End	
Reaction time / Assay points	10 / 21-33 (STAT 5 / 21-33)	
Wavelength (sub/main)	700/340 nm	
Reaction direction	Increase	
Units	mmol/L (g/L, mg/dL)	
Reagent pipetting	Diluent (H ₂ O)	
R1	50 µL	–
R2	50 µL	–

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H ₂ O)
Normal	4 µL	–	–
Decreased	2 µL	–	–
Increased	4 µL	–	–

cobas c 502 test definition

Assay type	2-Point End	
Reaction time / Assay points	10 / 21-33 (STAT 5 / 21-33)	
Wavelength (sub/main)	700/340 nm	
Reaction direction	Increase	
Units	mmol/L (g/L, mg/dL)	
Reagent pipetting	Diluent (H ₂ O)	
R1	50 µL	–
R2	50 µL	–

Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H ₂ O)
Normal	4 µL	–	–
Decreased	2 µL	–	–
Increased	8 µL	–	–

Calibration

Calibrators	S1: H ₂ O
-------------	----------------------

S2: Ammonia/Ethanol/CO₂ Calibrator

Calibration mode	Linear
Calibration frequency	2-point calibration - after reagent lot change - after 6 weeks on board - as required following quality control procedures

Traceability: This method has been standardized against NIST-traceable materials.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation^aRoche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	mmol/L x 0.04608 = g/L
	mmol/L x 4.608 = mg/dL
	g/L x 21.7 = mmol/L
	g/L x 100 = mg/dL

Limitations - interference

Criterion: Recovery within ± 10 % of initial value at an ethanol concentration of 21.7 mmol/L (1 g/L, 100 mg/dL).

Serum/plasmaIcterus:⁹ No significant interference up to an I index of 30 for conjugated bilirubin and 60 for unconjugated bilirubin (approximate conjugated bilirubin concentration: 513 µmol/L or 30 mg/dL; approximate unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).Hemolysis:⁹ No significant interference up to an H index of 200 (approximate hemoglobin concentration: 124.2 µmol/L or 200 mg/dL).Lipemia (Intralipid):⁹ No significant interference up to an L index of 500. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.Drugs: No interference was found at therapeutic concentrations using common drug panels.^{10,11}In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹²LDH/lactic acid (using a dose-response curve with purified LDH fractions added to a 30 mmol/L lactic acid solution): No significant interference at approximately 2000 U/L LDH. Significant positive interference at approximately 8000 U/L LDH.¹³**Urine**

No significant interference from glucose up to 111 mmol/L (2000 mg/dL), urea up to 333 mmol/L (2000 mg/dL), or creatinine up to 22.1 mmol/L (250 mg/dL).

CAUTION: Urine containing sugars and contaminated with microorganisms may yield a false positive result due to fermentation of sugar to alcohol.

CAUTION: Do not use volatile solvents in the work area when performing assays. Do not perform sample preparation (especially spiking of pools) in the immediate work area. Vapor contamination of reagents can impact calibration stability.

Drugs: No interference was found at therapeutic concentrations using common drug panels.¹¹**Serum/plasma/urine**The **cobas c** Ethanol Gen.2 reagent is specific for ethanol. The following cross-reactants were measured at 2000 mg/dL:

Compound	% cross-reactivity	% cross-reactivity	Repeatability	Mean	SD	CV
	(serum)	(urine)		mmol/L (g/L, mg/dL)	mmol/L (g/L, mg/dL)	%
n-Propanol	8.0	9.9	AEC Control N	10.9 (0.502, 50.2)	0.2 (0.009, 0.9)	1.6
n-Butanol	2.8	1.5	AEC Control A	32.5 (1.50, 150)	0.3 (0.01, 1)	0.9
Isopropanol	0.2	0.5	Human serum 1	19.7 (0.908, 90.8)	0.2 (0.009, 0.9)	1.2
Acetone	0.0	0.2	Human serum 2	75.8 (3.49, 349)	0.8 (0.04, 4)	1.1
Ethylene glycol	0.0	0.2	<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
Methanol	-0.1	0.2		<i>mmol/L (g/L, mg/dL)</i>	<i>mmol/L (g/L, mg/dL)</i>	<i>%</i>
Acetaldehyde	-1.1	-0.3	AEC Control N	11.1 (0.511, 51.1)	0.3 (0.01, 1)	2.4

$\frac{\text{mg/dL apparent ethanol}}{\text{mg/dL cross-reactant in sample}} \times 100 = \% \text{ cross-reactivity}$

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

Serum, plasma and urine

2.20-108 mmol/L (0.101-4.98 g/L, 10.1-498 mg/dL)

Specimen dilution

NOTE: Do not use automatic rerun.

Determine samples with higher concentrations via the decreased sample volume function. Use a fresh aliquot from a sample stored tightly closed. Reduction of sample volume via the decreased sample volume function represents a 1:2 dilution. These results are automatically multiplied by a factor of 2.

Lower limits of measurement

Lower detection limit

2.20 mmol/L (0.101 g/L, 10.1 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values^a

10.9-21.7 mmol/L (0.5-1 g/L, 50-100 mg/dL)	Flushing, slowing of reflexes, impaired visual acuity
> 21.7 mmol/L (> 1 g/L, > 100 mg/dL)	Depression of CNS
> 86.8 mmol/L (> 4 g/L, > 400 mg/dL)	Fatalities reported

The legal definition of intoxication varies according to local law. Each laboratory should establish an acceptable reporting format and identify procedures for the reporting of abnormal results. Clinical consideration and professional judgment should be applied to the interpretation of any alcohol test results.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Serum/plasma

<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L (g/L, mg/dL)</i>	<i>mmol/L (g/L, mg/dL)</i>	<i>%</i>
AEC Control N	11.1 (0.511, 51.1)	0.3 (0.01, 1)	2.4
AEC Control A	31.6 (1.46, 146)	0.4 (0.02, 2)	1.2
Human serum 3	26.9 (1.24, 124)	0.6 (0.03, 3)	2.0
Human serum 4	68.4 (3.15, 315)	0.8 (0.04, 4)	1.2

Urine

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L (g/L, mg/dL)</i>	<i>mmol/L (g/L, mg/dL)</i>	<i>%</i>
AEC Control N	10.9 (0.502, 50.2)	0.2 (0.009, 0.9)	1.6
AEC Control A	32.5 (1.50, 150)	0.3 (0.01, 1)	0.9
Human urine 1	21.0 (0.968, 96.8)	0.3 (0.01, 1)	1.4
Human urine 2	76.5 (3.53, 353)	0.6 (0.03, 3)	0.8
<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L (g/L, mg/dL)</i>	<i>mmol/L (g/L, mg/dL)</i>	<i>%</i>
AEC Control N	11.1 (0.511, 51.1)	0.3 (0.01, 1)	2.4
AEC Control A	31.6 (1.46, 146)	0.4 (0.02, 2)	1.2
Human urine 3	19.0 (0.876, 87.6)	0.4 (0.02, 2)	1.9
Human urine 4	34.5 (1.59, 159)	0.6 (0.03, 3)	1.8

Method comparison

Ethanol values for human serum, plasma and urine samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x).

Serum/plasma

Sample size (n) = 72

Passing/Bablok ¹⁴	Linear regression
$y = 1.023x + 0.090 \text{ mmol/L}$	$y = 1.020x + 0.248 \text{ mmol/L}$
$\tau = 0.988$	$r = 1.000$

The sample concentrations were between 2.67 and 94.1 mmol/L (0.123 and 4.34 g/L, 12.3 and 434 mg/dL).

Urine

Sample size (n) = 73

Passing/Bablok ¹⁴	Linear regression
$y = 1.008x + 0.288 \text{ mmol/L}$	$y = 1.007x + 0.261 \text{ mmol/L}$
$\tau = 0.982$	$r = 1.000$

The sample concentrations were between 2.85 and 97.1 mmol/L (0.131 and 4.47 g/L, 13.1 and 447 mg/dL).

References

- Kaplan LA, Pesce AJ. Clinical Chemistry, Theory, Analysis and Correlation. Ladig D, Kasper R (ed), St Louis, CV Mosby Co 1984;1332-1334.
- Bucher T, Redetzki H. Specific photometric determination of ethyl alcohol based on an enzymatic reaction. Klin Wschr 1951;29:615-616.

ETOH2

Ethanol Gen.2

- 3 Proposed guidelines NCCLS: Blood Alcohol Testing in the Clinical Laboratory. NCCLS Vol. 8 No. 10. December 1988.
- 4 Tietz NW. Fundamentals of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunder 1987;890.
- 5 Tietz NW, ed. Clinical Guide to Laboratory Tests, 4th ed. Philadelphia, PA: WB Saunders Company 2006;1344-1346.
- 6 Levine B, Smith ML. Stability of drugs of abuse in biological specimens. Forensic Sci Rev 1990;2:148-156.
- 7 Garriott JC, ed. Medicolegal Aspects of Alcohol. 3rd ed. Tucson, AZ: Lawyers & Judges Publishing Co, Inc 1996:262.
- 8 Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed. Philadelphia, PA: WB Saunders Company 1995;224-225.
- 9 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- 10 Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- 11 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- 12 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- 13 Nine JS, Moraca M, Virji MA, et al. Serum-ethanol determination: comparison of lactate and lactate dehydrogenase interference in three enzymatic assays. J of Anal Toxicol 1995 May-June;19(3):192-196.
- 14 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS and COBAS C are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2015, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336

